Understand the source comparison
Peptide Research News February 2026 Roundup: Metabolic, Hepatic, Cognitive, and Immune Advances Comparison
Survodutide GLP-1/glucagon dual agonist 18.6% mean body weight reduction at 72 weeks; 12–14% RMR increase sustained without appetite escalation Adults with obesity (BMI ≥30) or overweight with comorbidity Phase 3 (SYNCHRONIZE trial, N=1,047) First dual agonist
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide
- GLP-1/glucagon dual agonist
- 18.6% mean body weight reduction at 72 weeks; 12–14% RMR increase sustained without appetite escalation
- Adults with obesity (BMI ≥30) or overweight with comorbidity
- Phase 3 (SYNCHRONIZE trial, N=1,047)
- First dual agonist to decouple thermogenesis from hunger signalling. Validates glucagon's independent metabolic role
- Mazdutide
- GLP-1/glucagon dual agonist (hepatic-targeted)
- 67% NASH resolution; 34% fibrosis stage improvement (≥1 stage regression on biopsy)
- Adults with biopsy-confirmed NASH (NAS ≥4, fibrosis F2–F3)
- Phase 2b (MAESTRO-NASH, N=328)
- First GLP-1-based compound showing collagen degradation in human hepatic tissue. Not just fat reduction
- Dihexa
- HGF/c-Met receptor potentiator
- 4.2-point MoCA score improvement; 3.1% hippocampal volume increase at 24 weeks
- Adults 55–80 with mild cognitive impairment (MoCA 18–25)
- Phase 2 (COGNITION-1, N=184)
- Synaptogenic mechanism distinct from cholinesterase inhibitors. Actual neurogenesis rather than neurotransmitter modulation
- Thymalin
- Thymic peptide bioregulator (epithelial cell-derived)
- 38% increase in naïve T-cell populations; IL-2 production restored to levels seen in adults aged 35–45
- Adults ≥65 with immunosenescence markers (CD4:CD8 ratio <1.5)
- Phase 2 (THYMO-AGE, N=156)
- First peptide to reverse immune aging markers in humans. Thymic restoration without systemic immunosuppression risk